Screening tests for cancers in general, and breast, colon, and lung cancers specifically, have well known constraints and compliance shortcomings. Either the procedures are too invasive or they lack accuracy or the most effective diagnostics remain too expensive for widespread adoption for all those at greatest risk. Today’s battery of screenings are conducted too rarely or too late in the disease’s progression to allow for the most effective treatment.
The TBIA Platform
Reading the Response to Cancer
Todos Medical, Provista's parent company, has developed the “Total Biochemical Infrared Analysis” (TBIA) process, a proprietary screening of solid tumors using peripheral blood spectroscopy analysis. The process involves observing the immune system’s response to tumor presence rather than looking for the tumor cells themselves or specific markers. TBIA analyzes the entire biochemical signatures spectrum (including proteins, lipids, nucleic acids and carbohydrates) of effected immune cells from peripheral blood, using Fourier-transform infrared spectroscopy (FTIR).
Next Gen Early Detection
Evidence suggests that blood-based tests are the future of cancer screening. Our TBIA platform, represents a cost-effective, scalable, and patient-friendly screening practice for cancer detection.